Procept Biorobotics Stock

Procept Biorobotics EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Procept Biorobotics (PRCT) as of Aug 5, 2026 is -20.80. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -11.25 — a change of 84.83% (lower).

EV/FCF

-20.80

YoY

84.83%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Procept Biorobotics is 2026 -20.80 . EV/FCF (Enterprise Value to Free Cash Flow) of Procept Biorobotics was 2025 -11.25 . It decreases by 84.83% lower compared to the previous year.
Access this data via the Eulerpool API

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

EV/FCF (Enterprise Value to Free Cash Flow) of Procept Biorobotics is -20.80 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Procept Biorobotics changed from -11.25 to -20.80, representing a 84.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Procept Biorobotics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Procept Biorobotics

All Key Metrics — Procept Biorobotics